不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel:ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Prognostic value of interim [(18)F]FDG PET/CT after immunotherapy-based combinations in extranodal NK/T-cell lymphoma, nasal type.
Prognostic value of interim [(18)F]FDG PET/CT after immunotherapy-based combinations in extranodal NK/T-cell lymphoma, nasal type.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
免疫治疗为基础的全身治疗后的中期 PET/CT 对 ENKTL 显示出独立预后价值。将中期 PET/CT 与 PINK-E 联合的模型可能是一种有效的预后工具。问题 中期[18F]FDG PET/CT 在结外自然杀伤/T 细胞淋巴瘤中的预后价值仍不确定,尤其是在引入免疫治疗之后。发现 免疫治疗为基础的全身治疗后中期[18F]FDG PET/CT 上的 Deauville 5 分法是新诊断结外自然杀伤/T 细胞淋巴瘤的独立预测因素。临床意义 在免疫治疗时代,中期[18F]FDG PET/CT 单独或联合 NK 细胞淋巴瘤-Epstein-Barr 病毒预后指数(PINK-E)模型是一种有效且更优的临床应用预后工具。
评估结外NK/T细胞淋巴瘤(ENKTL)患者在接受以免疫治疗为基础的系统治疗后,中期[18F]氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描([18F]FDG PET/CT)的预后价值。
我们回顾性纳入133例新诊断鼻型ENKTL患者,这些患者在2-4个周期免疫治疗为基础的治疗后接受了中期[ 18 F]FDG PET/CT扫描。中期PET/CT通过最大标准化摄取值(SUV max)、Deauville 5分法(DS)和早期治疗反应进行判读。通过Kaplan-Meier分析生成生存曲线,并使用log-rank检验进行比较,评估总生存期(OS)和无进展生存期(PFS)的预后价值。进行单因素和多因素Cox比例风险分析,以评估对生存的独立影响。模型性能通过时间依赖性曲线下面积(time-AUC)、一致性指数(C-index)和赤池信息量准则(AIC)进行评估。
SUV max 高(> 9.2)、DS 5,或 interim PET/CT 显示疾病稳定(SD)或复发/进展(PD)的患者,Kaplan-Meier 估计分别显示 OS 和 PFS 显著不利。单因素和多因素分析后,interim PET/CT 参数仍是 OS 和 PFS 的独立预测因素。我们将 interim DS 与NK 细胞淋巴瘤预后指数-Epstein-Barr 病毒(PINK-E)模型结合,将我们的队列分为 3 个风险类别:低风险(0-2 个风险因素)、中等风险(3 个风险因素)和高风险(≥ 4 个风险因素),其对 OS 和 PFS 的分层显著且优于 PINK-E。
To evaluate the prognostic value of interim [ 18 F]Fluorodeoxyglucose positron emission tomography/computed tomography ([ 18 F]FDG PET/CT) after immunotherapy-based systemic therapies in extranodal natural killer/T-cell lymphoma (ENKTL).
We retrospectively recruited 133 newly diagnosed nasal-type ENKTL patients who underwent interim [ 18 F]FDG PET/CT scans after 2-4 cycles of immunotherapy-based treatments. Interim PET/CT was interpreted by maximum standardized uptake value (SUV max ), Deauville 5-point scale (DS), and early treatment response. The prognostic value of overall survival (OS) and progression-free survival (PFS) was assessed with survival curves generated using Kaplan-Meier analysis and compared using the log-rank test. Univariate and multivariate Cox proportional hazards analyses were performed to evaluate the independent effects for survival. Model performance was assessed with a time-dependent area under the curve (time-AUC), concordance index (C-index), and the Akaike information criterion (AIC).
Patients with high SUV max (> 9.2), DS 5, or with stable disease (SD) or relapsed/progressive disease (PD) on interim PET/CT showed significantly unfavorable OS and PFS with the Kaplan-Meier estimate, respectively. The interim PET/CT parameters remained independent predictors for both OS and PFS after univariate and multivariate analysis. We combined interim DS with the prognostic index for natural killer cell lymphoma-Epstein-Barr virus (PINK-E) model to stratify our cohort into 3 risk categories: low-risk (0-2 risk factors), intermediate-risk (3 risk factors), and high-risk (≥ 4 risk factors), which showed significant and superior stratifications of OS and PFS than PINK-E.
Interim PET/CT after immunotherapy-based systemic treatments showed independent prognostic value for ENKTL. The model combining interim PET/CT with PINK-E might be an effective prognostic tool. KEY POINTS: Question The prognostic value of interim [ 18 F]FDG PET/CT in extranodal natural killer/T-cell lymphoma remains uncertain, especially after the introduction of immunotherapy. Findings Deauville 5-point scale on interim [ 18 F]FDG PET/CT after immunotherapy-based systemic therapies was an independent predictor for newly diagnosed extranodal natural killer/T-cell lymphomas. Clinical relevance Interim [ 18 F]FDG PET/CT alone or combined with the prognostic index for natural killer cell lymphoma-Epstein-Barr virus (PINK-E) model is an effective and superior prognostic tool for clinical application in the era of immunotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。